drugset
drugset / Trial / NCT07494448

Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer

NCT07494448 ↗

Phase 1/2 Not yet recruiting 24 enrolled MedSIR
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The JAZMINE study is a multicenter, open-label, non-comparative, phase Ib/II clinical trial to evaluate safety and preliminary efficacy of zanidatamab in combination with tucatinib and chemotherapy (capecitabine or eribulin mesylate) in HER2-positive advanced breast cancer.

Timeline

Start
2026-07-01
Primary completion
2027-12-31
Completion
2028-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 650 mg/m2 Oral
Subject Capecitabine Small molecule 750 mg/m2 Oral
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Eribulin Small molecule 0.7 mg/m2 Intravenous
Subject Eribulin Small molecule 1.1 mg/m2 Intravenous
Subject Eribulin Small molecule 1.4 mg/m2 Intravenous
Subject Tucatinib Small molecule 300 mg Oral
Subject Zanidatamab Monoclonal antibody 1800 mg Intravenous
Subject Zanidatamab Monoclonal antibody 2400 mg Intravenous

Indications

HER2 positive breast carcinoma